Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Langer CJ¹, Gadgeel SM², Borghaei H³, Papadimitrakopoulou VA⁴, Patnaik A⁵, Powell SF⁶, Gentzler RD⁷, Martins RG⁸, Stevenson JP⁹, Jalal SI¹⁰,Panwalkar A¹¹, Yang JC¹², Gubens M¹³, Sequist LV¹⁴, Awad MM¹⁵, Fiore J¹⁶, Ge Y¹⁶, Raftopoulos H¹⁶, Gandhi L¹⁷; KEYNOTE-021 investigators.

Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.